{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:31:38Z","timestamp":1790857898788,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1136\/ard.2004.029058","type":"journal-article","created":{"date-parts":[[2004,11,26]],"date-time":"2004-11-26T01:13:34Z","timestamp":1101431614000},"page":"854-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus"],"prefix":"10.1016","volume":"64","author":[{"given":"M N","family":"Lub-de Hooge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E G E","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.029058_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00002281-200309000-00006","article-title":"Apoptosis in systemic lupus erythematosus","volume":"5","author":"White","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2004.029058_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.genet.33.1.29","article-title":"Fas ligand-induced apoptosis","volume":"33","author":"Nagata","year":"1999","journal-title":"Annu Rev Genet"},{"key":"10.1136\/ard.2004.029058_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1054\/mehy.1997.0712","article-title":"Fas\/Fas ligand on the road: an apoptotic pathway common to AIDS, autoimmunity, lymphoproliferation and transplantation","volume":"53","author":"Famularo","year":"1999","journal-title":"Med Hypotheses"},{"key":"10.1136\/ard.2004.029058_bib4","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.7510905","article-title":"Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule","volume":"263","author":"Cheng","year":"1994","journal-title":"Science"},{"key":"10.1136\/ard.2004.029058_bib5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.1780400617","article-title":"Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases","volume":"40","author":"Nozawa","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.029058_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1136\/ard.2004.029058_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1136\/ard.2004.029058_bib8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.55.7.928","article-title":"Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS","volume":"55","author":"Huang","year":"2000","journal-title":"Neurology"},{"key":"10.1136\/ard.2004.029058_bib9","first-page":"791","article-title":"Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome","volume":"20","author":"Matsumura","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2004.029058_bib10","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.4049\/jimmunol.169.10.6020","article-title":"The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells","volume":"169","author":"Kaplan","year":"2002","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.029058_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/clim.2001.5182","article-title":"Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array","volume":"102","author":"Rus","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1136\/ard.2004.029058_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2249.2001.01418.x","article-title":"Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE)","volume":"123","author":"Bijl","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2004.029058_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2003-12-4274","article-title":"TNF related apoptosis inducing ligand is involved in neutropenia of systemic lupus erythematosus","volume":"104","author":"Matsuyama","year":"2004","journal-title":"Blood"},{"key":"10.1136\/ard.2004.029058_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.029058_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.029058_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1191\/096120301701548517","article-title":"Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity","volume":"10","author":"Bijl","year":"2001","journal-title":"Lupus"},{"key":"10.1136\/ard.2004.029058_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.029058_bib18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.029058_bib19","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/art.11237","article-title":"Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus","volume":"48","author":"Ren","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.029058_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.188.2.387","article-title":"Systemic exposure to irradiated apoptotic cells induces autoantibody production","volume":"188","author":"Mevorach","year":"1998","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2004.029058_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1365-2249.1996.44754.x","article-title":"Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE)","volume":"104","author":"Spronk","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2004.029058_bib22","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.4049\/jimmunol.167.12.6736","article-title":"Differential secretion of Fas ligand- or APO2 ligand\/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells","volume":"167","author":"Monleon","year":"2001","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.029058_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-3083.2000.00671.x","article-title":"Lipopolysaccharide induces expression of APO2 ligand\/TRAIL in human monocytes and macrophages","volume":"51","author":"Halaas","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.2004.029058_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2004.029058_bib25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1084\/jem.189.8.1343","article-title":"Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL","volume":"189","author":"Griffith","year":"1999","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2004.029058_bib26","article-title":"IFN\u03b1-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL\/Apo-2 ligand) displaying apoptotic activity on leukemic cells","volume":"15","author":"Tecchio","year":"2004","journal-title":"Blood"},{"key":"10.1136\/ard.2004.029058_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1074\/jbc.M107795200","article-title":"Molecular cross-talk between the TRAIL and interferon signaling pathways","volume":"277","author":"Kumar-Sinha","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2004.029058_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard.2004.029058_bib29","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4049\/jimmunol.166.2.1314","article-title":"Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis","volume":"166","author":"Hilliard","year":"2001","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.029058_bib30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1084\/jem.191.7.1095","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression","volume":"191","author":"Song","year":"2000","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2004.029058_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni894","article-title":"Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL\u2212\/\u2212 mice","volume":"4","author":"Lamhamedi-Cherradi","year":"2003","journal-title":"Nat Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724429725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724429725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.029058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:23:08Z","timestamp":1736140988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724429725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0003496724429725"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.029058","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.029058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}